These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26279669)

  • 1. HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users.
    Budambula V; Musumba FO; Webale MK; Kahiga TM; Ongecha-Owuor F; Kiarie JN; Sowayi GA; Ahmed AA; Ouma C; Were T
    AIDS Res Ther; 2015; 12():27. PubMed ID: 26279669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users.
    Ndombi EM; Budambula V; Webale MK; Musumba FO; Wesongah JO; Mibei E; Ahmed AA; Lihana R; Were T
    Endocr Connect; 2015 Dec; 4(4):223-32. PubMed ID: 26306727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran.
    Memarnejadian A; Menbari S; Mansouri SA; Sadeghi L; Vahabpour R; Aghasadeghi MR; Mostafavi E; Abdi M
    PLoS One; 2015; 10(5):e0126955. PubMed ID: 25962088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
    Lambert-Niclot S; Grude M; Chaix ML; Charpentier C; Reigadas S; Le Guillou-Guillemette H; Rodallec A; Amiel C; Maillard A; Dufayard J; Mourez T; Mirand A; Guinard J; Montes B; Vallet S; Marcelin AG; Descamps D; Flandre P; Delaugerre C; Morand-Joubert L;
    J Antimicrob Chemother; 2018 Aug; 73(8):2147-2151. PubMed ID: 29718247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene.
    Kowalski J; Gange SJ; Schneider MF; Tsai HL; Templeton A; Shao Q; Zhang GW; Yeh MF; Young M; Markham RB
    J Acquir Immune Defic Syndr; 2009 Apr; 50(4):381-9. PubMed ID: 19214121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.
    Elmi Abar A; Jlizi A; Darar HY; Kacem MA; Slim A
    Diagn Pathol; 2012 Oct; 7():138. PubMed ID: 23044036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference.
    Han X; Zhang M; Dai D; Wang Y; Zhang Z; Liu J; Geng W; Jiang Y; Takebe Y; Shang H
    AIDS Res Hum Retroviruses; 2007 Mar; 23(3):357-64. PubMed ID: 17411368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Difference in Prevalence of Transmitted Drug Resistance between Injection Drug Users and Non-Injection Drug Users: A Cross-Sectional Study among Antiretroviral Treatment-Naïve HIV Patients.
    Chen R; Liang B; Wen B; Huang G; Ning C; Lao C; Jiang J; Liu J; Zhou B; Huang J; Chen J; Zang N; Liao Y; Mo D; Ye L; Liang H
    Intervirology; 2018; 61(6):281-291. PubMed ID: 31018203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.
    Wood E; Hogg RS; Yip B; Dong WW; Wynhoven B; Mo T; Brumme CJ; Montaner JS; Harrigan PR
    AIDS; 2005 Jul; 19(11):1189-95. PubMed ID: 15990572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.
    Parbie PK; Abana CZ; Kushitor D; Asigbee TW; Ntim NAA; Addo-Tetebo G; Ansong MRD; Ofori SB; Mizutani T; Runtuwene LR; Nishizawa M; Ishikawa K; Kiyono H; Ampofo WK; Matano T; Bonney EY; Kikuchi T
    Front Microbiol; 2022; 13():973771. PubMed ID: 36090108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
    J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 drug resistance-associated mutations among HIV-1 infected drug-naïve antenatal clinic attendees in rural Kenya.
    Kiptoo M; Brooks J; Lihana RW; Sandstrom P; Ng'ang'a Z; Kinyua J; Lagat N; Okoth F; Songok EM
    BMC Infect Dis; 2013 Nov; 13():517. PubMed ID: 24180455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China.
    Zhong P; Kang L; Pan Q; Konings F; Burda S; Ma L; Xue Y; Zheng X; Jin Z; Nyambi P
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):91-101. PubMed ID: 14501800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and Non-injection drug users from coastal Kenya.
    Webale MK; Budambula V; Lihana R; Musumba FO; Nyamache AK; Budambula NL; Ahmed AA; Ouma C; Were T
    BMC Infect Dis; 2015 Jul; 15():299. PubMed ID: 26223795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.